PIK3CA and neoplasm: Our results here demonstrate that early suppression of ctDNA predicts long-term outcome substantially earlier than changes in tumor size, when truncal mutations such as PIK3CA are tracked in plasma, in the setting of palbociclib with fulvestrant in advanced hormone receptor-positive breast cancer.